Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:

NCT ID: NCT01850277 Recruiting - Heart Failure Clinical Trials

Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study

Pilot-CRAfT
Start date: October 2013
Phase: Phase 4
Study type: Interventional

The purpose of this prospective randomized study is to determine whether patients on cardiac resynchronization therapy with concomitant long-standing persistent or permanent atrial fibrillation would benefit from a strategy to restore and maintain sinus rhythm (rhythm control strategy) in comparison to a rate control strategy in terms of higher biventricular paced beats percentage.

NCT ID: NCT01837771 Recruiting - Heart Failure Clinical Trials

Epiphrenic III Pilot Trial

Start date: April 2013
Phase: N/A
Study type: Interventional

The Epiphrenic III Pilot Trial investigates whether a diaphragmatic stimulation by interventionally placed electrodes may improve heart function, symptoms and functional capacity in patients with severe heart failure.

NCT ID: NCT01832493 Recruiting - Heart Failure Clinical Trials

Sensor Optimization of Cardiac Resynchronization Therapy Response

SOCR
Start date: July 2013
Phase: N/A
Study type: Interventional

The Sensor Optimization of Cardiac Resynchronization Therapy (CRT) Response (SOCR) Study is a multicenter, prospective, non-randomized acute feasibility study that is being conducted to determine if subcutaneous heart sounds and/or intracardiac impedance can acutely identify the optimal atrioventricular (AV) pacing intervals and optimal left ventricular (LV) electrodes in patients indicated for cardiac resynchronization therapy.

NCT ID: NCT01829880 Recruiting - Clinical trials for Chronic Heart Failure

Impact of Body Composition on Bisoprolol and Ramipril Pharmacokinetics in Patients With Chronic Heart Failure

Start date: October 2011
Phase: N/A
Study type: Observational

The purpose of this study is to determine if cachexia and changes in body composition influence pharmacokinetics of bisoprolol and ramipril and the accuracy of equations for renal function estimation.

NCT ID: NCT01829126 Recruiting - Clinical trials for Congestive Heart Failure

Development and Prevention of Severe Heart Disease in Systemic Sclerosis

Start date: April 2013
Phase: N/A
Study type: Observational [Patient Registry]

Systemic sclerosis is an orphan, multiorgan disease affecting the connective tissue of the skin and all internal organs. Cardiac involvement, mainly characterised by small intramyocardial coronary artery involvement and myocardial fibrosis, can cause the development of impaired diastolic ventricular filling, cardiac blocks and ventricular arrhythmias, and can ensue in congestive heart failure and sudden death. Until now, no drug has been proven to have a therapeutic effect on SSc myocardial disease on an evidence-based level. Short-term trials and retrospective studies have suggested a favourable and protective effect of calcium channel blockers and angiotensin converting enzyme inhibitors in patients with myocardial involvement. However, no data are presently available on the prevention and treatment of severe heart disease. This observational trial is part of the collaborative project "DeSScipher", one out of five observational trials to decipher the optimal management of systemic sclerosis. Aim of this observational trial is to assess the efficacy and safety of calcium channel blockers and angiotensin converting enzyme inhibitors in asymptomatic SSc patients with cardiac involvement.

NCT ID: NCT01792258 Recruiting - Heart Failure Clinical Trials

Procedures and Follow-up of Percutaneous Tracheostomy in Intensive Care Unit

Start date: June 2012
Phase: N/A
Study type: Observational

Tracheostomy is worldwide performed in Intensive Care Unit (ICU). According to the current literature, indication for percutaneous tracheostomy (PDT) in ICU are: difficult prolonged weaning, prolonged mechanical ventilation, loss of airway reflex, copious secretions, upper airway obstruction. Many studies have focused on the comparison between different PDT techniques and complication. The aim of our study is to evaluate the procedural features, complications, ICU mortality, quality of life, post-discharge mortality of patients undergoing different PDT techniques performed in ICU.

NCT ID: NCT01790906 Recruiting - Clinical trials for Chronic Heart Failure

Renal Sympathetic Denervation for Patients With Chronic Heart Failure

RSD4CHF
Start date: January 2013
Phase: N/A
Study type: Interventional

To study whether renal sympathetic denervation(RSD) RSD can slow the progression of CHF and reduce the rate of all-cause mortality effectively and securely.

NCT ID: NCT01780597 Recruiting - Heart Failure Clinical Trials

Assessment of Hearts Deemed Unsuitable for Transplant With the Aim of Expanding the Donor Heart Pool.

Start date: February 2013
Phase:
Study type: Observational

The main question to be asked in this study is what is the potential for human hearts that have been deemed unacceptable for transplant, to be explanted and re-animated in a controlled, external environment to be assessed? Furthermore would the reanimated hearts be able to undergo improvement in their function in this external environment. Ultimately this may lead to an increase the number of hearts available for transplantation.

NCT ID: NCT01777607 Recruiting - Right Heart Failure Clinical Trials

The Use of Impella RP Support System in Patients With Right Heart Failure

Start date: May 2013
Phase: N/A
Study type: Interventional

The use of Impella RP is safe, feasible and provides a hemodynamic benefit in patients with right ventricular failure.

NCT ID: NCT01774656 Recruiting - Clinical trials for Heart Failure NYHA Class III

Remission From Stage D Heart Failure

RESTAGE-HF
Start date: January 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the proportion of subjects who have sufficient improvement in ventricular function after undergoing a standardized Left Ventricular Assist Device (LVAD) plus pharmacologic recovery treatment and testing protocol to allow removal of the LVAD within 18 months.